Ranbaxy Laboratories surged 4.83 per cent to close at Rs 263.85 based on reports that the US Department of Justice (DoJ) may withdraw the motion against the firm next week, which was initiated in a local US court. Besides, the government on Friday approved Daiichi Sankyo’s investment in Ranbaxy.
Daiichi has been given the green light to buy 34.8 per cent from the promoters along with an open offer for a further 20 per cent from the authorities. Ranbaxy touched an intraday high of Rs 274.7 and a low of Rs 254, with trading volumes of 32,62,773.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app